AOP 3.13% 33.0¢ apollo consolidated limited

demise, page-3

  1. 89 Posts.
    lightbulb Created with Sketch. 12
    Dear ANDYJAMESH,
    According to AOP;s company announcement on the 10 july
    it states it wishes to advance its clinical therapeutic candidates including oral TNF blocker and oral insulin.
    Hopefully the company can raise the finances and get up
    and become a going concern.
    If the company can get the oral insulin clinical trials up and running and show that oral insulin works and is safe
    they will be onto a winner.Would have profound implications
    for the future management for diabetics and would
    revolutionise future treatment.
 
watchlist Created with Sketch. Add AOP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.